Matches in Wikidata for { <http://www.wikidata.org/entity/Q73042231> ?p ?o ?g. }
Showing items 1 to 67 of
67
with 100 items per page.
- Q73042231 description "article scientifique publié en 1999" @default.
- Q73042231 description "artículu científicu espublizáu n'ochobre de 1999" @default.
- Q73042231 description "im Oktober 1999 veröffentlichter wissenschaftlicher Artikel" @default.
- Q73042231 description "scientific article published on 01 October 1999" @default.
- Q73042231 description "wetenschappelijk artikel" @default.
- Q73042231 description "наукова стаття, опублікована в жовтні 1999" @default.
- Q73042231 name "Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial" @default.
- Q73042231 name "Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial" @default.
- Q73042231 type Item @default.
- Q73042231 label "Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial" @default.
- Q73042231 label "Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial" @default.
- Q73042231 prefLabel "Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial" @default.
- Q73042231 prefLabel "Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial" @default.
- Q73042231 P1433 Q73042231-0A8C215A-5EC4-4A2C-ABC6-F1CF0672DA18 @default.
- Q73042231 P1476 Q73042231-C6543E2B-8D26-426B-8151-13B1D5DBC5FC @default.
- Q73042231 P2093 Q73042231-019362F4-DD71-41A6-A051-056266188C08 @default.
- Q73042231 P2093 Q73042231-0C60F520-49A7-4BFE-B2C5-381F76EB93C0 @default.
- Q73042231 P2093 Q73042231-1648C690-778F-4E4D-9744-387A6ED6D4FB @default.
- Q73042231 P2093 Q73042231-41AB248B-C238-46D2-B715-5502F8415D8D @default.
- Q73042231 P2093 Q73042231-41DBC3B0-8E3F-4934-9D2D-EC6C4245E054 @default.
- Q73042231 P2093 Q73042231-64CEE224-6BB2-4AC9-9D83-99A765AA4323 @default.
- Q73042231 P2093 Q73042231-68E1DDB7-EF42-4567-A7D8-6512AB8AF46F @default.
- Q73042231 P2093 Q73042231-8D78C5AD-E0AC-4B97-8F15-AB8619F8EDB6 @default.
- Q73042231 P2093 Q73042231-8F17B2D7-FD4E-447E-BF0B-43D2400E82A9 @default.
- Q73042231 P2093 Q73042231-BD597864-C611-4E9C-96F7-386B0D2BF77D @default.
- Q73042231 P2093 Q73042231-CE80C8E6-B5DA-4B0B-9C3A-BB6EFD31BF97 @default.
- Q73042231 P2093 Q73042231-DB9B4065-799F-430F-AE07-F89E2AE7EBFB @default.
- Q73042231 P2093 Q73042231-E5684BF0-97F8-4525-87CA-890B34E2F941 @default.
- Q73042231 P304 Q73042231-14E5F464-744D-46D0-B5E4-C7371A45E8B4 @default.
- Q73042231 P31 Q73042231-6307FB1D-3B04-4E59-A3FC-D9E6579B8E52 @default.
- Q73042231 P356 Q73042231-2336BDDD-B6CA-4874-A0F2-6D7927FEA646 @default.
- Q73042231 P407 Q73042231-AF921268-87FA-44A2-AFE5-9FDCE9E164DB @default.
- Q73042231 P433 Q73042231-69FDB0DF-8BA2-45FF-972D-8F69D82E3445 @default.
- Q73042231 P478 Q73042231-81E4C8C3-38C7-45FD-B582-CDC1A306552E @default.
- Q73042231 P577 Q73042231-57D0FF31-A54F-4F2D-BBF8-6A3616BED24E @default.
- Q73042231 P698 Q73042231-605FFD61-A100-4DED-9F63-F6C26D39BD15 @default.
- Q73042231 P921 Q73042231-1F07AAEB-1321-47B3-BA26-DFD06DB4B794 @default.
- Q73042231 P921 Q73042231-9DB29B1A-9CAD-4D99-B70B-8CA9C9BD1ACA @default.
- Q73042231 P921 Q73042231-F509A2E9-F21A-4DBF-B7B4-E591ED8C3178 @default.
- Q73042231 P356 JCO.1999.17.10.3160 @default.
- Q73042231 P698 10506613 @default.
- Q73042231 P1433 Q400292 @default.
- Q73042231 P1476 "Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial" @default.
- Q73042231 P2093 "A Balsham" @default.
- Q73042231 P2093 "B Roth" @default.
- Q73042231 P2093 "E Ross" @default.
- Q73042231 P2093 "F Monaco" @default.
- Q73042231 P2093 "G Hudes" @default.
- Q73042231 P2093 "H Ramsey" @default.
- Q73042231 P2093 "J Sprandio" @default.
- Q73042231 P2093 "L Einhorn" @default.
- Q73042231 P2093 "M Entmacher" @default.
- Q73042231 P2093 "M Hanna" @default.
- Q73042231 P2093 "P Loehrer" @default.
- Q73042231 P2093 "R Ansari" @default.
- Q73042231 P2093 "W Dugan" @default.
- Q73042231 P304 "3160-3166" @default.
- Q73042231 P31 Q13442814 @default.
- Q73042231 P356 "10.1200/JCO.1999.17.10.3160" @default.
- Q73042231 P407 Q1860 @default.
- Q73042231 P433 "10" @default.
- Q73042231 P478 "17" @default.
- Q73042231 P577 "1999-10-01T00:00:00Z" @default.
- Q73042231 P698 "10506613" @default.
- Q73042231 P921 Q181257 @default.
- Q73042231 P921 Q282629 @default.
- Q73042231 P921 Q42824827 @default.